Condom Makers Are Fighting a New Problem: Younger Consumers Are Buying Less

That shift matters because condoms sit at the crossroads of public health and everyday retail. They are sold in pharmacies, supermarkets, vending machines, e-commerce platforms, and health clinics. Yet sales patterns have become less predictable. In Japan, one of the clearest examples, researchers and public agencies have for years documented lower sexual frequency among younger adults. A long-running survey by the Japan Family Planning Association has repeatedly found a significant share of married couples reporting no sex for extended periods. Other studies in Europe and North America have also pointed to declining sexual activity among younger people, especially after the pandemic disrupted social routines. For manufacturers, that means the old belief that every new generation will buy roughly the same products in roughly the same way no longer holds.

The numbers behind the market show both scale and strain. Global condom sales still total billions of units each year, and the broader sexual wellness market remains large. Industry estimates often place the global condom market in the range of $10 billion to $15 billion annually, depending on what products are counted and which regions are included. But headline market size can hide a tougher reality. Growth is uneven. In mature markets, volume is often flat. In lower-income regions, demand may be high but consumers are price sensitive and public-sector procurement plays a major role. The World Health Organization and UNAIDS have continued to stress the importance of condoms in HIV prevention, especially in sub-Saharan Africa and parts of Asia. Yet from a business view, those public health needs do not always translate into strong consumer-brand growth.

The pressure is coming from several directions at once. One is demographic. Birth rates are falling in many developed countries, and people are marrying later. Another is behavioral. Research from the U.S. Centers for Disease Control and Prevention and other health agencies has shown that many teenagers and young adults are delaying sexual activity compared with previous generations. Some surveys have linked that change to more screen time, economic anxiety, changing social habits, and a different approach to dating. If people have sex less often, they buy fewer condoms. It is a simple equation, but one with major consequences for companies that built production, marketing, and distribution around a more stable pattern of use.

A second problem is substitution. Condoms are not only competing with rival condom brands. They are competing with other forms of birth control and with changing ideas about risk. Long-acting reversible contraceptives, including implants and intrauterine devices, have gained wider acceptance in many countries. Those options do not protect against infection, but they reduce the need for condoms as pregnancy prevention. In some markets, that has weakened the product’s position in relationships where disease risk is perceived to be low. Public health experts have warned that this creates a dangerous gap, especially as STI rates have risen in several countries. In the United States, for example, CDC surveillance has shown large increases in reported cases of syphilis and other infections over the past decade. That trend underlines a hard truth for the industry: the social need for condoms remains strong even when consumer habits move in the other direction.

A third challenge is retail economics. Condoms are often treated as a low-margin staple, especially in stores where buyers compare prices quickly and buy based on convenience. Private-label products and discount packs can put pressure on branded manufacturers. Meanwhile, latex prices, energy costs, and shipping expenses have all added strain in recent years. Malaysia and Thailand, two major centers for rubber and condom manufacturing, have faced swings in labor and supply conditions. During the pandemic, some producers benefited from strong demand in medical gloves, but that boom also disrupted parts of the wider latex goods business. For condom companies, that has meant balancing commodity cost risk with a consumer base that is often unwilling to pay much more.

The result is an industry trying to reinvent itself without losing its core purpose. Some companies have moved upmarket, selling ultra-thin, non-latex, textured, or premium-lubricated products at higher margins. Others are trying to make condoms feel less clinical and less awkward to buy. Direct-to-consumer startups have used discreet shipping, cleaner packaging, and subscription models to target younger buyers who may avoid store purchases out of embarrassment. In India, where the market includes both mass public-health distribution and strong private brands, companies have long leaned on bold advertising and lifestyle positioning. In Europe and North America, the language has shifted toward wellness, comfort, and design.

But branding alone cannot solve a demand problem rooted in deeper social change. If younger adults are more isolated, more financially stressed, or less likely to form stable relationships early, no package redesign will fully restore old buying patterns. This is why some executives increasingly speak about category expansion rather than simple market share. They want to sell adjacent products such as lubricants, home sexual health kits, and broader wellness items. That strategy reflects a recognition that the condom, by itself, may no longer offer the growth profile investors once expected in richer markets.

There is also a public-interest issue that business leaders cannot ignore. When condom sales weaken, the impact is not just corporate. It can affect infection prevention, family planning access, and health equity. In many countries, lower-income consumers rely on free or subsidized condoms distributed by governments and aid groups. If commercial incentives weaken too far, private producers may become more dependent on institutional contracts and less willing to invest in product innovation for mass markets. That would be a mistake. Better fit, better feel, and easier access all matter. Research has long shown that discomfort, poor fit, and stigma reduce consistent use.

The smarter response is likely to be a mix of business discipline and public-health realism. Companies need to keep investing in product quality and affordability rather than assuming premium branding will carry the category. Retailers can improve access through less stigmatized placement, vending options, and online fulfillment. Governments and health systems should keep funding education that treats condoms not as old-fashioned backup but as a frontline tool against infection. And manufacturers would benefit from listening more closely to younger consumers, who often say they want convenience, privacy, and products that feel designed for them rather than for a lecture from the past.

The condom industry is not disappearing. Its role is too important, and the market is still too large. But it is entering a more difficult phase, one where demand cannot be taken for granted. The companies that survive will be the ones that understand a subtle but powerful change in modern life: even essential products can falter when social behavior shifts. In this business, that shift is not just a sales problem. It is a warning sign about health, intimacy, and the economy that younger adults are inheriting.